



May 10, 2007

Dr. Stephen Sundlof
FDA Center for Veterinary Medicine
7519 Standish Place
Rockville, MD 20855

Dear Dr. Sundlof:

The American Horse Council is the national association representing all aspects of the horse industry in Washington, D.C. It includes over 160 organizations representing every facet of the horse world – from owners, breeders, trainers, veterinarians, farriers, breed registries and horsemen’s associations to horse shows, racetracks, rodeos, commercial suppliers and state horse councils.

The American Horse Council has been receiving a significant amount of input from the horse industry regarding their concern over the potential shortage of Pergolide, a drug which is used to treat Cushing’s disease in horses, also known as pituitary pars intermedia dysfunction (PPID). This concern stems from the FDA’s decision in March to withdraw the drug from the market due to certain side effects it was causing in humans using the drug to treat Parkinson’s disease. The AHC would like to express to you the importance of this critical drug within the equine industry and urge you to do whatever is necessary to allow for its continued availability to the industry.

We understand that for Pergolide to be available to the horse industry, an exemption is needed from FDA requirements that would approve the importation of the bulk, raw ingredient for veterinary purposes and would allow the compounding pharmacies to obtain the product and continue the production of Pergolide. We ask that you please do what is necessary to permit the continued production of Pergolide for use in the equine industry.

Thank you for your careful and timely consideration on this matter. If we can be of any assistance in getting your message to the horse industry, we would be happy to help. If you have any questions, please feel free to contact me.

Sincerely,

A handwritten signature in blue ink that reads "James J. Hickey, Jr.".

James J. Hickey, Jr.
President